Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
|
29901113 |
2018 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
This starts with the new GhrasT-NIH/Swiss cell line that was produced from the NIH/3T3 cell line that had been transformed by transfection with HRAS oncogene DNA from the T24 human bladder carcinoma.
|
26254261 |
2016 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that mosaicism for oncogenic HRAS mutations may increase the risk for developing BC at a young age.
|
24169525 |
2014 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
It is evident from our study that HRAS T81C SNP moderately increases bladder cancer risk, and rare allele is a predictive marker of advanced bladder tumors.
|
21514184 |
2013 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Analysis of HRAS gene TRR methylation showed that the methylation level of HRAS has clinical relevance (P = 0.0049, by unpaired Student's t test) with bladder cancer.
|
22707223 |
2012 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
HRAS is a proto-oncogene involved in the tumorigenesis of urinary bladder cancer.
|
21931711 |
2011 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All together, co-existence of Aurora-A overexpression and Ha-ras mutation suggests a possible additively effect on the tumorigenesis of bladder cancer.
|
16338065 |
2006 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
HRAS1 genotype may be related to the prognosis of bladder cancer, however, because incident cases, i.e., newly diagnosed cases had a higher frequency of rare alleles than did prevalent cases, i.e., cases already existing at the time of recruitment.
|
12115522 |
2002 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The observation that these cell lines have p53 and Ha-ras mutations identical to those in bladder carcinoma cell line T24 prompted us to investigate their possible interrelations.
|
11522622 |
2001 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the bladder cancer cell lines were subjected to sequence analysis to identify a point mutation in the c-H-ras gene at codon 12.
|
10995035 |
2000 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Cells of two human bladder carcinoma cell lines were used, one with a mutated oncogenic HRAS (T24) and other with a wild-type HRAS (RT4).
|
10856967 |
2000 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The effects of 7-hydroxycoumarin, genistein and quercetin on two ras-oncogene-driven tumour cells (rat breast adenocarcinoma and human bladder carcinoma) were investigated using cellular (proliferation and migration) and molecular targets (p21ras GTPase activity and intracellular amount of p21ras protein).
|
8642043 |
1996 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The c-Ha-ras-1 locus was studied by Southern blotting in white blood cells and tumor samples obtained from 126 patients with bladder cancer (74 Ta-T1 and 52 T2-T4).
|
8583569 |
1996 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions.
|
8352563 |
1993 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
The induction of gene mutations and chromosome aberrations by plasmid pEJ6.6 carrying the activated c-Ha-ras-1 oncogene from human bladder carcinoma was studied in cultured Chinese hamster cells.
|
1521228 |
1992 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Contrary to this, endogenous activated Ha-ras in a human bladder carcinoma cell line, T24, was not eliminated by BA.
|
1773788 |
1991 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
The non tumorigenic human mammary cell line HBL100 has been transformed by the EJ/T24 human bladder carcinoma Harvey(Ha)-ras oncogene.
|
1861862 |
1991 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
We showed previously that diploid human fibroblasts that express a transfected HRAS oncogene from the human bladder carcinoma cell line T24 exhibit several characteristics of transformed cells but do not acquire an infinite life-span and are not tumorigenic.
|
2643097 |
1989 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
c-Ha-ras-1 alleles in bladder cancer, Wilms' tumour and malignant melanoma.
|
2892780 |
1988 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
Activation and/or overexpression of the protein product of the ras gene family (p21ras) has been implicated in the development of various cancers, including bladder carcinoma.
|
3057152 |
1988 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene.
|
3409229 |
1988 |
Carcinoma of bladder
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomes isolated from a human bladder carcinoma cell line which contains the actively transforming oncogene HRAS1 on chromosome 11 can be used to transform mouse cells.
|
3474107 |
1987 |
Carcinoma of bladder
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
On the other hand, deletion of one Ha-ras allele was observed in 1 of 5 cases of bladder cancer and in 2 of 3 cases of renal pelvic cancer, suggesting that that deletion may be important in the development of urothelial cancer.
|
2889677 |
1987 |
Carcinoma of bladder
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Suppression of tumorigenicity with continued expression of the c-Ha-ras oncogene in EJ bladder carcinoma-human fibroblast hybrid cells.
|
3523486 |
1986 |